Literature DB >> 21457681

Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network.

Irene Petersen1, Ruth E Gilbert, Stephen J W Evans, Shuk-Li Man, Irwin Nazareth.   

Abstract

BACKGROUND: Potential adverse effects of antidepressants during pregnancy have caused concern about their use. There are, however, very limited detailed data on patterns of antidepressant prescribing in pregnancy.
OBJECTIVE: To examine secular trends in prescribing during pregnancy, to assess whether pregnancy is a major determinant for stopping antidepressants, and to identify characteristics of those who stopped antidepressants during pregnancy.
METHOD: In this cohort study, we obtained data on 114,999 pregnant women (median age at delivery, 30.5 years [interquartile range, 26-34 years]) who had a live birth between 1992 and 2006 and 22,677 nonpregnant women from The Health Improvement Network primary care database, one of the largest sources of continuous anonymized primary care data in the United Kingdom and broadly representative of UK general practice. This database includes information on age, sex, medical diagnosis and symptoms, health promotion activities, referrals to secondary care, and prescriptions for each registered individual. The database also holds information about social deprivation as measured using quintiles of the Townsend score. We used Cox regression analysis to compare time to last prescription in pregnant versus nonpregnant women and to identify characteristics of those women who stopped antidepressants during pregnancy.
RESULTS: Antidepressant prescribing in pregnancy increased nearly 4-fold from 1992 to 2006 (relative risk = 3.87; 95% CI, 1.73-8.66; P < .001). Since 2001, approximately 3% of the cohort received antidepressants at some stage during pregnancy. Selective serotonin reuptake inhibitors accounted for approximately 80% of the prescribed antidepressants. Antidepressants were more likely to be stopped in pregnant than in nonpregnant women, in particular during the first 6 weeks of pregnancy (hazard ratio = 5.19; 95% CI, 4.85-5.56; P < .001). Only 10% of women treated before pregnancy still received antidepressants at the start of the third trimester. In contrast, 35% of nonpregnant women were still treated after a similar time period.
CONCLUSIONS: Although antidepressant prescribing in pregnancy increased nearly 4-fold from 1992 to 2006, pregnancy was a major determinant of cessation of antidepressant medication, and most women did not receive further antidepressant prescriptions beyond 6 weeks of gestation. This finding may be explained by concerns about potential adverse effects of the medications, even though these concerns need to be balanced against the potential harm of inadequate treatment of depression during pregnancy. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21457681     DOI: 10.4088/JCP.10m06090blu

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  62 in total

1.  Pharmacoepidemiology.

Authors:  Stephen J W Evans
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Patterns of prescription of antidepressants and antipsychotics across and within pregnancies in a population-based UK cohort.

Authors:  Andrea V Margulis; Elizabeth M Kang; Tarek A Hammad
Journal:  Matern Child Health J       Date:  2014-09

3.  Computer-assisted cognitive behavioral therapy for pregnant women with major depressive disorder.

Authors:  Deborah R Kim; Liisa Hantsoo; Michael E Thase; Mary Sammel; C Neill Epperson
Journal:  J Womens Health (Larchmt)       Date:  2014-09-30       Impact factor: 2.681

Review 4.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

5.  Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study.

Authors:  Anthony Wemakor; Karen Casson; Ester Garne; Marian Bakker; Marie-Claude Addor; Larraitz Arriola; Miriam Gatt; Babak Khoshnood; Kari Klungsoyr; Vera Nelen; Mary O'Mahoney; Anna Pierini; Anke Rissmann; David Tucker; Breidge Boyle; Lolkje de Jong-van den Berg; Helen Dolk
Journal:  Eur J Epidemiol       Date:  2015-07-07       Impact factor: 8.082

6.  Psychotropic Drug Use before, during, and after Pregnancy: A Population-Based Study in a Canadian Cohort (2001-2013).

Authors:  Christine Leong; Colette Raymond; Dan Château; Matthew Dahl; Silvia Alessi-Severini; Jamie Falk; Shawn Bugden; Alan Katz
Journal:  Can J Psychiatry       Date:  2017-05-25       Impact factor: 4.356

7.  Pregnancy and the Acceptability of Computer-Based Versus Traditional Mental Health Treatments.

Authors:  Liisa Hantsoo; Jessica Podcasy; Mary Sammel; Cynthia Neill Epperson; Deborah R Kim
Journal:  J Womens Health (Larchmt)       Date:  2017-04-20       Impact factor: 2.681

Review 8.  Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise.

Authors:  Tamar L Gur; Deborah R Kim; C Neill Epperson
Journal:  Psychopharmacology (Berl)       Date:  2013-05-17       Impact factor: 4.530

9.  Perinatal mental health: a review of progress and challenges.

Authors:  Louise M Howard; Hind Khalifeh
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

Review 10.  The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.

Authors:  Anick Bérard; Noha Iessa; Sonia Chaabane; Flory T Muanda; Takoua Boukhris; Jin-Ping Zhao
Journal:  Br J Clin Pharmacol       Date:  2016-01-26       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.